Gout management is a comprehensive therapeutic strategy aimed at treating acute inflammatory arthritis flares and addressing the root cause: chronic hyperuricemia (elevated serum uric acid). According to guidelines from the American College of Rheumatology (ACR 2020) and the European Alliance of Associations for Rheumatology (EULAR 2016), effective management requires a dual approach. First, short-term anti-inflammatory agents rapidly suppress joint pain during acute flares. Second, ongoing urate-lowering therapy reduces serum urate levels below target thresholds to dissolve monosodium urate crystals and prevent long-term joint erosion.

Gout management involves a stepped pharmacological approach. For acute flares, treatment begins immediately with oral nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or systemic corticosteroids to inhibit inflammatory pathways. Once acute inflammation subsides, clinicians evaluate indications for long-term urate-lowering therapy (ULT), such as xanthine oxidase inhibitors (allopurinol or febuxostat) or uricosuric agents (probenecid). ULT is initiated at a low dose and gradually increased every 2 to 4 weeks based on serial serum urate measurements. Prophylactic anti-inflammatory therapy with low-dose colchicine or NSAIDs is co-administered during the first 3 to 6 months of ULT to prevent mobilization flares caused by crystal dissolution.

Evidence-based gout management effectively eliminates acute joint flares, prevents progressive joint destruction, and dissolves established soft-tissue tophi. Sustained reduction of serum urate levels below clinical targets stops crystal deposition and improves overall quality of life. Guidelines from the British Society for Rheumatology (BSR 2017) confirm that long-term urate-lowering therapy significantly reduces emergency department visits, preserves renal function, and decreases overall systemic inflammation associated with gout.

Resolution of an acute gout flare typically occurs within 7 to 14 days when prompt anti-inflammatory treatment is initiated. Long-term recovery and disease suppression depend on adherence to urate-lowering therapy. While initial medication adjustments may take 3 to 6 months to reach target serum urate levels, complete dissolution of tissue urate crystals and elimination of recurrent flares generally require 12 to 24 months of continuous, targeted medical therapy.

Gout management treats acute gouty arthritis, chronic tophaceous gout, recurrent gout flares, and hyperuricemia-associated joint erosion. It also helps manage secondary risks associated with persistent high uric acid levels, such as uric acid nephrolithiasis (kidney stones) and gout-related chronic kidney disease.

Before starting long-term gout management, patients undergo baseline diagnostic evaluation. This includes measuring serum uric acid levels, assessing renal function via serum creatinine and estimated glomerular filtration rate (eGFR), checking liver enzymes, and screening for metabolic comorbidities such as hypertension, diabetes, and dyslipidemia. In patients of Asian ancestry (such as Han Chinese, Thai, or Korean origin), genetic screening for the HLA-B*5801 allele is recommended before initiating allopurinol to minimize the risk of severe cutaneous adverse reactions.

Complications and side effects vary depending on the specific pharmacological agents used. Common mild side effects include self-limiting gastrointestinal distress from colchicine or NSAIDs, mild skin rashes, or temporary mobilization flares when initiating urate-lowering therapy. Less common risks include acute kidney injury from heavy NSAID use, transient liver enzyme elevation, or moderate hypersensitivity reactions. Rare but severe complications include Allopurinol Hypersensitivity Syndrome (AHS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), colchicine toxicity, and cardiovascular adverse events associated with specific xanthine oxidase inhibitors.

The patient journey in gout management begins with an accurate clinical diagnosis during or immediately following an acute flare, often confirmed through physical examination, serum urate testing, or joint fluid aspiration. Once acute inflammation is controlled using anti-inflammatory medications, clinicians evaluate the patient for long-term urate-lowering therapy. Patients undergo baseline blood testing, including kidney function and liver enzyme evaluations, before initiating low-dose urate-lowering medications alongside anti-flare prophylaxis. Regular follow-up appointments every four to twelve weeks allow clinicians to titrate medication dosages until serum urate falls below target thresholds, followed by annual monitoring to ensure sustained disease remission.